Tuberculosis vaccine development; From mouse to man

Microbes and Infection

Volumn 7, Issue 5-6, 2005, Pages 922-931

  Reed, Steven ^a   Lobet, Yves ^b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; Antigen; Tuberculosis; Vaccine

Indexed keywords

85 B; 85 C; AS 01B; AS 01B VACCINE; AS 02A; AS 02A VACCINE; BACTERIAL ANTIGEN; BCG VACCINE; CFP ANTIGEN; DNA VACCINE; ESAT 6; LIVE VACCINE; MPF ANTIGEN; MPT 83; MSF ANTIGEN; MSG ANTIGEN; MTB 11; MTB 12; MTB 14; MTB 32; MTB 32 VACCINE; MTB 35 VACCINE; MTB 39; MTB 39A; MTB 40; MTB 41; MTB 72 VACCINE; MTB 72F; MTB 72F VACCINE; MTB 8.4; MTB 9.8; MTB 9.9; RV 0125; RV 0129C; RV 0287; RV 0915C; RV 1174C; RV 1196; RV 1793; RV 1886C; RV 2031C; RV 2873; RV 3616C; RV 3763; RV 3874; RV 3875; TB 636; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; GENOMICS; GUINEA PIG; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR CLONING; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINE PRODUCTION;

CAVIA; ORYCTOLAGUS CUNICULUS;

EID: 20444503715     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.03.011     Document Type: Article

References (24)

1. P.E. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 1995 1339 1345
2. Editorial BCG vaccination after the Madras study Lancet 1 1981 309 310
3. P.E. Fine The BCG story: lessons from the past and implications for the future Rev. Infect. Dis. 11 Suppl. 2 1989 S353 S359 S353-S359
4. A.M. Ginsberg What's new in tuberculosis vaccines? Bull. Who 80 2002 483 488
5. P. Andersen Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins Infect. Immun. 62 1994 2536 2544
6. M.R. Alderson, T. Bement, C.H. Day, L. Zhu, D. Molesh, Y.A. Skeiky, R. Coler, D.M. Lewinsohn, S.G. Reed, and D.C. Dillon Expression Cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells J. Exp. Med. 191 2000 551 560
7. L. Brandt, M. Elhay, I. Rosenkrands, E.B. Lindblad, and P. Andersen ESAT-6 subunit vaccination against Mycobacterium tuberculosis Infect. Immun. 68 2000 791 795
8. R.N. Coler, A. Campos-Neto, P. Ovendale, F.H. Day, S.P. Fling, L. Zhu, N. Serbina, J.L. Flynn, S.G. Reed, and M.R. Alderson Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis J. Immunol. 166 2001 6227 6235
9. D.C. Dillon, M.R. Alderson, C.H. Day, D.M. Lewinsohn, R. Coler, T. Bement, A. Campos-Neto, Y.A. Skeiky, I.M. Orme, A. Roberts, S. Steen, W. Dalemans, R. Balaro, and G.S. Reed Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family Infect. Immun. 67 1999 2941 2950
10. Y.A. Skeiky, M.J. Lodes, J.A. Guderian, R. Mohamath, T. Bement, M.R. Alderson, and S.G. Reed Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis Infect. Immun. 67 1999 3998 4007
11. Y.A. Skeiky, P.J. Ovendale, S. Jen, M.R. Alderson, D.C. Dillon, S. Smith, C.B. Wilson, I.M. Orme, S.G. Reed, and A. Campos-Neto T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection J. Immunol. 165 2000 7140 7149
12. O.A. Weinrich, L.A. Van Pinxteren, O.L. Meng, R.P. Birk, and P. Andersen Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6 Infect. Immun. 69 2001 2773 2778
13. D.F. Hoft, R.M. Brown, and R.B. Belshe Mucosal bacille Calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses Clin. Infect. Dis. 30 Suppl. 3 2000 S217 S222 S217-S222
14. J.V. Brooks, A.A. Frank, M.A. Keen, J.T. Bellisle, and I.M. Orme Boosting vaccine for tuberculosis Infect. Immun. 69 2001 2714 2717
15. C.G. Feng, U. Palendira, C. Demangel, J.M. Spratt, A.S. Malin, and W.J. Britton Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis Infect. Immun. 69 2001 4174 4176
16. J.F. Griffin, C.G. Mackintosh, L. Slobbe, A.J. Thomson, and G.S. Buchan Vaccine protocols to optimise the protective efficacy of BCG Tubercle Lung Dis. 79 1999 135 143
17. J.F. Griffin, D.N. Chinn, C.R. Rodgers, and C.G. Mackintosh Optimal models to evaluate the protective efficacy of tuberculosis vaccines Tuberculosis (Edinb.) 81 2001 133 139
18. H. McShane, R. Brookes, S.C. Gilbert, and A.V. Hill Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis Infect. Immun. 69 2001 681 686
19. S. Worku, and D.F. Hoft In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin Clin. Infect. Dis. 30 Suppl. 3 2000 S257 S261
20. S.G. Reed, M.R. Alderson, W. Dalemans, Y. Lobet, and Y.A.W. Skeiky Prospects for a better vaccine against tuberculosis Tuberculosis (Edinb.) 83 2003 213 219
21. L. Brandt, Y.A. Skeiky, M.R. Alderson, Y. Lobet, W. Dalemans, O.C. Turner, R.J. Basaraba, A.A. Izzo, T.M. Lasco, P.L. Chapman, S.G. Reed, and I.M. Orme The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kDa fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs Infect. Immun. 72 2004 6622 6632
22. Y.A. Skeiky, M.R. Alderson, P.J. Ovendale, J.A. Guderian, L. Brandt, D.C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I.M. Orme, and S.G. Reed Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein J. Immunol. 172 2004 7618 7628
23. L. Tsenova, Y.A.W. Skeiky, E. Ellison, W. Dalemans, S.G. Reed, G. Kaplan, Anti-tuberculosis vaccine evaluation using a rabbit model. TB Vaccines for the World, Montreal, Canada, September 17-19, 2003 (Abstract).
24. P.L. Alonso, J. Sacarlal, J.J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M.M. Navia, S. Corachan, M. Ceuppens, M.C. Dubois, M.A. Demoitie, F. Dubovsky, C. Menendez, N. Tornieporth, W.R. Ballou, R. Thompson, and J. Cohen Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Lancet 364 2004 1411 1420